Impax Asset Management Group plc Sells 25,000 Shares of Prestige Consumer Healthcare Inc. $PBH

Impax Asset Management Group plc lessened its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 18.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 110,000 shares of the company’s stock after selling 25,000 shares during the quarter. Impax Asset Management Group plc owned 0.22% of Prestige Consumer Healthcare worth $8,784,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. UMB Bank n.a. boosted its holdings in Prestige Consumer Healthcare by 81.8% in the second quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after acquiring an additional 144 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Prestige Consumer Healthcare by 312.5% in the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock valued at $26,000 after buying an additional 250 shares in the last quarter. Maseco LLP purchased a new stake in shares of Prestige Consumer Healthcare during the second quarter worth about $27,000. First Horizon Advisors Inc. raised its stake in Prestige Consumer Healthcare by 294.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 599 shares of the company’s stock valued at $48,000 after purchasing an additional 447 shares during the last quarter. Finally, Geneos Wealth Management Inc. raised its holdings in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after acquiring an additional 269 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $59.84 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38. The stock has a market cap of $2.88 billion, a PE ratio of 14.05, a P/E/G ratio of 1.93 and a beta of 0.41. The stock has a fifty day moving average price of $62.44 and a 200 day moving average price of $72.69. Prestige Consumer Healthcare Inc. has a 1 year low of $59.18 and a 1 year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 6th. The company reported $1.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The firm had revenue of $274.11 million during the quarter, compared to the consensus estimate of $257.14 million. During the same period in the previous year, the firm posted $1.09 EPS. The company’s quarterly revenue was down 3.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on PBH shares. Wall Street Zen downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Jefferies Financial Group decreased their price objective on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating for the company in a research report on Monday, October 27th. Oppenheimer decreased their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a report on Tuesday, October 21st. Canaccord Genuity Group reduced their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Finally, Sidoti raised Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 target price for the company in a report on Wednesday, September 24th. Four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.